Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 13/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048010 | 0.89 | ADK (0.45) | ADKMETTL3SLC29A1PI4KAPI4K2B | |
| SCHEMBL18297616 | 0.88 | ADK (0.49) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17549902 | 0.85 | HTR2B (0.38) | ADKSLC29A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29610855 | 0.84 | ADK (0.43) | ADKMETTL3SLC29A1PI4KAPI4K2B | |
| SCHEMBL24314271 | 0.84 | ADK (0.43) | ADKMETTL3SLC29A1PI4KAPI4K2B | |
| SCHEMBL25046663 | 0.84 | ADK (0.46) | ADKMETTL3SLC29A1 | |
| SCHEMBL24314267 | 0.82 | ADK (0.43) | ADKMETTL3 | |
| SCHEMBL20488512 | 0.82 | ADK (0.43) | ADKMETTL3 | |
| SCHEMBL31617998 | 0.81 | ADK (0.44) | ADKMETTL3 | |
| SCHEMBL31617994 | 0.81 | ADK (0.44) | ADKMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | ADK 1700/4885METTL3 166/4885SLC29A1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.